To see our newsletters, Press release and TV coverage click here.

To see our research initiatives news click here

To see our webinars explaining the science behind the projects we are supporting click here

Copy of Copy of Copy of Smiths' AnnualDue to the COVID-19 pandemic, we had to postpone our April 3rd, NF2 Novel Therapies consortium in Boston.

We had 45 NF2 and Gene Therapy researchers and clinicians that were planning to attend from all over USA and europe.



Here below was our agenda:
*Welcoming statement +NF2 BioSolutions updates
*Patients perspectives – living with NF2
*Guests introduction (per group)

*Merlin targeted gene-based therapy approaches to NF2:

1. Clinical advances in CNS-directed gene therapy. From target to drug.
2. Current molecular understanding of NF2-associated Merlin mutations and their impact on protein function. Panel discussion.
3. Data Present/Plans from Nationwide group – Dr Meyer
4. Data Present/Plans from Mueller group – Dr Meijboom
5. Data Present/Plans from Dr. Castellano/Dr. Blanco
6. Group Discussion: Challenges/Milestones/Timelines

*Merlin-independent cell- and immuno-based therapy approaches to NF2:

1. Clinical advances in cell-based and immuno-based therapies.
2. Data Present/Plans from Gary Brenner and Sherif Ahmed + discussions
3. Discussion: Challenges/Milestones/Timelines

*Testimony living with NF2 + Coffee Break

*Cementing the basis for research and clinical studies through collaborations: Tumor bank, Biomarkers, Animal models and Natural History

1. Human Schwann Cell Model Systems for NF2. + Group discussion
2. Tissue Bank Kick off Discussion/stakeholder/partnership commitments + Group discussion
3. NF2 Animal models landscape. + Group discussion
4. Natural history study: NIH in action+ Group discussion
5. Discussion: Challenges/Milestones/Timelines

*New Approaches

*Next Steps

We hope we can reschedule the meeting asap once the pandemic is over. In the meantime we will continue to interact with the researcher remotely.

April 3rd 2020: Kickoff of the first Open-Access NF2 Tissue/Cell bank to accelerate Screen Shot 2020-02-24 at 12.33.46existing research and attract new labs into the race of curing NF2. Today it is very complicated for a research lab to have access to NF2 tumors (frozen/fresh), cell lines and genome sequencing data. This initiative will solve the access problem, we are going to collect tissue sample from many surgeons, performing analysis on them and share the data as well as the tissues. NF2 Cell line will be created as well and shared. For more info go here.

Gene Replacement Therapy for NF2 is starting!

August 1st 2019NF2 BioSolutions signed a contract in July 2019 to partially fund a NF2 Kathrin MeyerGene therapy Pilot Pre-Clinical Study at the Abigail Wexner Research Institute at Nationwide Children’s Hospital by Dr. Kathrin Meyer, who is serving as the Principal Investigator.

Read more…

June 26th 2019:  Dr. Mueller of the University of Massachusetts Medical School attended NF2 BioSolutions’s NF2 Gene Therapy 16-chris-mueller.jpgconsortium in Boston on March 29th. Being moved by the impact of NF2, Dr. Mueller decided to start a gene therapy pilot study to determine if his lab’s gene therapy platform could be a good candidate for tackling the NF2 mutation. The advantage of his platform is its ability to silence the mutated gene and then add a healthy one. Dr. Mueller, assisted by Dr. Karin Meijboom, will be financing the development of the gene therapy NF2 vector for the pilot. Once manufactured, it will be tested on NF2 in order to determine efficiency. NF2 BioSolutions will facilitate the collaboration between the NF2 experts and Dr. Mueller’s lab.

This is just the beginning, there is much more to come!!! We need your continuing support as we shine the spotlight on NF2. Our goal is to collaborate with several leading gene therapy labs and share findings as we go to increase our chances of finding a long term solution for NF2.

Take a look at the impressive Mueller lab (the site is not yet updated with his new NF2 focus).

March 29th 2019:  NF2 Gene Therapy Consortium

56403785_2297907090452213_2851512097295040512_oNF2 BioSolutions organized the first NF2 Gene Therapy Consortium where participated more than 40 biotech executives, researchers & clinicians from NF2 or leading Gene Therapy labs. Click here for more informations


Buy merchandise to support research

Screen Shot 2019-06-26 at 17.41.19To buy merchandise, click here to see all the choices of t-shirts, cups, magnets… Fifty % of sales go to NF2 BioSolutions.



Article on WebMD about Nicole Henwood, founder of NF2 BioSolutions

Screen Shot 2019-06-30 at 9.50.38


Mom Blazes Path to Cure for Son’s Rare Disease

Click here to read the article in WebMD about Dr Nicole Henwood, president of NF2 BioSolution.






Upcoming Events


Click here to Follow us on Facebook and don’t miss our updates:

3 weeks ago

NF2 BioSolutions

We are thrilled to announced that Dr. Brad Welling is joining our Scientific Advisory Board.
His decades of experience with NF2 will be invaluable to our research projects.

To check out his bio along with the biographies of the other Scientific Advisory Board members, click here :

Dr. Welling is the Walter Augustus Lecompte Professor and Chair of the Harvard Department of Otolaryngology Head and Neck Surgery and Chief of Otolaryngology Head and Neck Surgery at Massachusetts Eye and Ear and Massachusetts General Hospital.
He received his MD from the University of Utah, his residency in Otolaryngology-Head and Neck Surgery at the University of Iowa, and fellowship in Otology, Neurotology, and Cranial Base Surgery at the EAR Foundation in Nashville, Tennessee. He completed a PhD in pathobiology at The Ohio State University.
Dr. Welling has a long-standing interest in finding better treatment solutions for NF2. He and his collaborators have defined phenotype-genotype relationships, characterized the promoter region of the NF2 gene, and contributed relevant pathway mechanisms for merlin-deficient tumors. He has conducted and participated in multiple clinical trials intent on finding better treatment options for NF2. His clinical practice has focused on the surgical removal of vestibular schwannomas and on hearing preservation and restoration.
Professionally, Dr Welling has served on the Board of Directors of the American Board of Otolaryngology Head and Neck Surgery, and on the Residency Review Committee of the Accreditation Council on Graduate Medical Education (ACGME). He serves as the inaugural Editor-in-Chief of Laryngoscope Investigative Otolaryngology.

View on Facebook

4 weeks ago

NF2 BioSolutions

Today at 3PM EST, don't forget. Register here: ...

View on Facebook

4 weeks ago

NF2 BioSolutions

Below is from Kim Whitlock, who is part of the NF2 BioSolutions UK team


Hello from the newly-formed UK team. We are all eager to get involved with local communities here and NF2 BioSolutions teams from around the world to spread awareness, information of the exciting progress made and raise some much needed funds for research for better treatments to help individuals live the best lives they can with NF2.

The team is currently working together to develop fund raising ideas and welcome tips, ideas, and fundraisers from the wider community. We have recently set up Easyfundraising, the easy way to donate every time you shop online, just search NF2 BioSolutions UK. Also, look out for our new Facebook page - which is coming soon.

View on Facebook

1 month ago

NF2 BioSolutions

CereXis and NF2 BioSolutions invite you to learn about NF2 from the experts. Our panelists include Dr. D. Bradley Welling, Chief of Otolaryngology–Head and Neck Surgery at Massachusetts Eye and Ear and Prof D Gareth Evans, Professor of Med. Genetics and Cancer Epidemiology, The University of Manchester, UK.
Please register here:

View on Facebook

2 months ago

NF2 BioSolutions

We're on Facebook and we're on YouTube too! If you haven't subscribed, you can do so here at

By-and-large, it's a good way to keep updated about what we're doing in our fight against NF2. We'll have videos of our fundraisers and recordings of our webinars, all viewable wherever, whenever.

View on Facebook


Translate »
search previous next tag category expand menu location phone mail time cart zoom edit close